Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 19/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7698849 | 0.87 | CYP19A1 (0.52) | CYP19A1 | |
| SCHEMBL1656805 | 0.81 | AR (0.58) | CYP19A1 | |
| SCHEMBL13809834 | 0.81 | AR (0.58) | CYP19A1 | |
| SCHEMBL1868136 | 0.77 | CYP19A1 (0.52) | CYP19A1 | |
| SCHEMBL8402137 | 0.75 | CYP19A1 (0.50) | CYP19A1 | |
| SCHEMBL3658069 | 0.75 | CYP19A1 (0.65) | CYP19A1 | |
| SCHEMBL11022948 | 0.71 | CYP19A1 (0.58) | CYP19A1 | |
| SCHEMBL7698847 | 0.71 | CYP19A1 (0.50) | CYP19A1 | |
| SCHEMBL1860990 | 0.70 | CYP19A1 (0.46) | CYP19A1 | |
| SCHEMBL1867163 | 0.69 | CYP19A1 (0.46) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0920441-A1 | 7ALPHA-(EPSILON-AMINOALKYL)-ESTRATRIENES, PROCESS FOR PREPARING THE SAME, PHARMACEUTICAL PREPARATIONS CONTAINING SAID 7ALPHA-(EPSILON-AMINOALKYL)-ESTRATRIENES AND THEIR USE FOR PREPARING MEDICAMENT | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-06-09 | — | — | EP | disclosed |
| WO-1998007740-A1 | 7α-(κ-AMINOALKYL)ESTRATRIENES, PROCESS FOR PREPARING THE SAME, PHARMACEUTICAL PREPARATIONS CONTAINING SAID 7α-(κ-AMINOALKYL)ESTRATRIENES AND THEIR USE FOR PREPARING MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-02-26 | — | — | WO | disclosed |